| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 75 | 2026 | 1196 | 11.790 |
Why?
|
| Brain Ischemia | 52 | 2025 | 421 | 10.730 |
Why?
|
| Leukoaraiosis | 13 | 2019 | 45 | 5.560 |
Why?
|
| Thrombectomy | 31 | 2025 | 241 | 5.460 |
Why?
|
| Brain Injuries, Traumatic | 7 | 2025 | 99 | 3.900 |
Why?
|
| Infarction, Middle Cerebral Artery | 22 | 2025 | 87 | 3.820 |
Why?
|
| White Matter | 7 | 2020 | 123 | 3.490 |
Why?
|
| Endovascular Procedures | 27 | 2025 | 607 | 3.210 |
Why?
|
| Thrombolytic Therapy | 18 | 2025 | 193 | 3.130 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2024 | 127 | 3.060 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 854 | 2.860 |
Why?
|
| Cerebrovascular Circulation | 20 | 2025 | 183 | 2.860 |
Why?
|
| Retrospective Studies | 76 | 2026 | 6740 | 2.800 |
Why?
|
| Fibrinolytic Agents | 14 | 2025 | 173 | 2.720 |
Why?
|
| Vertebral Artery Dissection | 10 | 2026 | 20 | 2.710 |
Why?
|
| Severity of Illness Index | 19 | 2024 | 1561 | 2.670 |
Why?
|
| Aged | 96 | 2026 | 14662 | 2.570 |
Why?
|
| Male | 138 | 2026 | 30322 | 2.560 |
Why?
|
| Aged, 80 and over | 61 | 2025 | 5528 | 2.560 |
Why?
|
| Anticoagulants | 17 | 2025 | 511 | 2.530 |
Why?
|
| Treatment Outcome | 68 | 2025 | 5696 | 2.340 |
Why?
|
| Intracranial Hemorrhages | 8 | 2024 | 68 | 2.300 |
Why?
|
| Middle Aged | 91 | 2026 | 17921 | 2.170 |
Why?
|
| Brain Concussion | 4 | 2023 | 37 | 2.070 |
Why?
|
| Female | 105 | 2026 | 33382 | 1.940 |
Why?
|
| Embolism | 6 | 2020 | 41 | 1.830 |
Why?
|
| Disease Models, Animal | 22 | 2025 | 2238 | 1.820 |
Why?
|
| Carotid Artery, Internal, Dissection | 10 | 2026 | 19 | 1.780 |
Why?
|
| Cerebral Infarction | 10 | 2022 | 84 | 1.750 |
Why?
|
| Brain | 21 | 2023 | 1581 | 1.730 |
Why?
|
| Humans | 144 | 2026 | 64283 | 1.710 |
Why?
|
| Magnetic Resonance Imaging | 30 | 2025 | 2218 | 1.650 |
Why?
|
| Mechanical Thrombolysis | 5 | 2025 | 37 | 1.630 |
Why?
|
| Heart Diseases | 3 | 2022 | 220 | 1.580 |
Why?
|
| Armadillo Domain Proteins | 3 | 2025 | 27 | 1.560 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 15 | 2021 | 155 | 1.510 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2025 | 508 | 1.470 |
Why?
|
| Risk Factors | 36 | 2026 | 5341 | 1.460 |
Why?
|
| Recovery of Function | 9 | 2019 | 286 | 1.460 |
Why?
|
| Intracranial Thrombosis | 9 | 2024 | 29 | 1.450 |
Why?
|
| Cytoskeletal Proteins | 3 | 2025 | 206 | 1.440 |
Why?
|
| Venous Thrombosis | 7 | 2024 | 112 | 1.370 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2015 | 119 | 1.320 |
Why?
|
| Ischemic Attack, Transient | 9 | 2026 | 97 | 1.220 |
Why?
|
| Brain Injuries | 4 | 2020 | 142 | 1.190 |
Why?
|
| Neuroimaging | 8 | 2022 | 155 | 1.120 |
Why?
|
| Rats | 28 | 2018 | 2005 | 1.120 |
Why?
|
| Long QT Syndrome | 2 | 2021 | 32 | 1.090 |
Why?
|
| Carotid Stenosis | 3 | 2024 | 98 | 1.070 |
Why?
|
| Superoxide Dismutase-1 | 2 | 2025 | 143 | 1.060 |
Why?
|
| Time Factors | 25 | 2024 | 3725 | 1.000 |
Why?
|
| Reperfusion | 7 | 2024 | 37 | 1.000 |
Why?
|
| Animals | 49 | 2025 | 20967 | 0.990 |
Why?
|
| Cerebral Hemorrhage | 9 | 2025 | 100 | 0.980 |
Why?
|
| Registries | 16 | 2025 | 885 | 0.960 |
Why?
|
| Cortical Spreading Depression | 4 | 2020 | 9 | 0.950 |
Why?
|
| Cost of Illness | 3 | 2015 | 169 | 0.940 |
Why?
|
| Brain Infarction | 5 | 2021 | 21 | 0.940 |
Why?
|
| Aspirin | 4 | 2025 | 172 | 0.920 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2025 | 233 | 0.910 |
Why?
|
| Frontotemporal Dementia | 2 | 2023 | 154 | 0.870 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2023 | 11 | 0.860 |
Why?
|
| Pick Disease of the Brain | 1 | 2023 | 6 | 0.830 |
Why?
|
| Predictive Value of Tests | 9 | 2024 | 1105 | 0.820 |
Why?
|
| C9orf72 Protein | 2 | 2023 | 114 | 0.810 |
Why?
|
| Geniculate Bodies | 1 | 2023 | 2 | 0.800 |
Why?
|
| Axons | 3 | 2023 | 126 | 0.780 |
Why?
|
| Pancreatitis | 1 | 2023 | 98 | 0.750 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 215 | 0.740 |
Why?
|
| Recurrence | 12 | 2026 | 652 | 0.740 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 1669 | 0.730 |
Why?
|
| Prognosis | 12 | 2024 | 1769 | 0.720 |
Why?
|
| Chronic Traumatic Encephalopathy | 1 | 2021 | 5 | 0.700 |
Why?
|
| Neurons | 6 | 2023 | 934 | 0.700 |
Why?
|
| Tauopathies | 1 | 2021 | 19 | 0.690 |
Why?
|
| Intracranial Embolism | 5 | 2014 | 39 | 0.680 |
Why?
|
| Adult | 27 | 2026 | 17134 | 0.670 |
Why?
|
| Troponin | 2 | 2020 | 39 | 0.660 |
Why?
|
| Risk Assessment | 11 | 2024 | 2048 | 0.660 |
Why?
|
| Electroencephalography | 3 | 2020 | 151 | 0.650 |
Why?
|
| Embolization, Therapeutic | 3 | 2025 | 328 | 0.640 |
Why?
|
| Electrocardiography | 2 | 2021 | 554 | 0.630 |
Why?
|
| Rats, Wistar | 12 | 2017 | 187 | 0.620 |
Why?
|
| Vitamin K | 1 | 2019 | 16 | 0.620 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2010 | 625 | 0.610 |
Why?
|
| Weight Loss | 1 | 2021 | 276 | 0.610 |
Why?
|
| Cognition | 2 | 2022 | 491 | 0.600 |
Why?
|
| Mice | 12 | 2025 | 11004 | 0.590 |
Why?
|
| Hematoma | 1 | 2019 | 80 | 0.590 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 25 | 0.580 |
Why?
|
| Propensity Score | 5 | 2025 | 167 | 0.570 |
Why?
|
| Reperfusion Injury | 3 | 2021 | 56 | 0.570 |
Why?
|
| Stroke Rehabilitation | 1 | 2019 | 50 | 0.570 |
Why?
|
| Disability Evaluation | 4 | 2024 | 218 | 0.570 |
Why?
|
| Diffuse Axonal Injury | 1 | 2018 | 4 | 0.560 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2018 | 10 | 0.560 |
Why?
|
| Nucleic Acids | 1 | 2019 | 60 | 0.550 |
Why?
|
| Hyperoxia | 2 | 2008 | 17 | 0.550 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 7 | 0.530 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 165 | 0.520 |
Why?
|
| Warfarin | 4 | 2024 | 122 | 0.520 |
Why?
|
| Length of Stay | 2 | 2019 | 819 | 0.520 |
Why?
|
| Stroke Volume | 1 | 2018 | 330 | 0.510 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 271 | 0.510 |
Why?
|
| Motor Activity | 2 | 2019 | 346 | 0.500 |
Why?
|
| Thrombophilia | 2 | 2020 | 14 | 0.490 |
Why?
|
| Eligibility Determination | 1 | 2016 | 36 | 0.490 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 749 | 0.480 |
Why?
|
| Hemorrhage | 7 | 2024 | 275 | 0.480 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 848 | 0.470 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.470 |
Why?
|
| Stroke, Lacunar | 1 | 2015 | 4 | 0.460 |
Why?
|
| Post-Concussion Syndrome | 1 | 2015 | 4 | 0.460 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 115 | 0.460 |
Why?
|
| Myxoma | 1 | 2015 | 13 | 0.460 |
Why?
|
| Cohort Studies | 11 | 2025 | 2605 | 0.450 |
Why?
|
| Embolism, Paradoxical | 1 | 2015 | 14 | 0.450 |
Why?
|
| Critical Care | 1 | 2019 | 402 | 0.450 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 13 | 0.450 |
Why?
|
| Glasgow Outcome Scale | 1 | 2014 | 17 | 0.450 |
Why?
|
| Heart Neoplasms | 1 | 2015 | 36 | 0.450 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 42 | 0.450 |
Why?
|
| Patient Selection | 2 | 2016 | 487 | 0.430 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2012 | 65 | 0.420 |
Why?
|
| Middle Cerebral Artery | 4 | 2018 | 50 | 0.420 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 107 | 0.420 |
Why?
|
| Infarction | 3 | 2023 | 20 | 0.420 |
Why?
|
| Myocardial Infarction | 2 | 2024 | 915 | 0.420 |
Why?
|
| Vitamin D | 1 | 2015 | 139 | 0.420 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2013 | 7 | 0.410 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 45 | 0.410 |
Why?
|
| Sinus Thrombosis, Intracranial | 2 | 2024 | 7 | 0.410 |
Why?
|
| Cerebral Arterial Diseases | 2 | 2011 | 8 | 0.410 |
Why?
|
| Temporal Lobe | 1 | 2013 | 46 | 0.410 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2013 | 24 | 0.410 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 930 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 708 | 0.400 |
Why?
|
| Behavior, Animal | 4 | 2007 | 234 | 0.390 |
Why?
|
| Venous Thromboembolism | 3 | 2024 | 147 | 0.390 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2140 | 0.380 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 25 | 0.380 |
Why?
|
| Brain Death | 1 | 2012 | 17 | 0.380 |
Why?
|
| Mice, Transgenic | 3 | 2025 | 1297 | 0.380 |
Why?
|
| Stents | 3 | 2025 | 492 | 0.360 |
Why?
|
| Neuroprotective Agents | 3 | 2009 | 77 | 0.360 |
Why?
|
| Linear Models | 4 | 2020 | 408 | 0.360 |
Why?
|
| Cell Death | 4 | 2007 | 286 | 0.360 |
Why?
|
| Anesthesia, General | 2 | 2024 | 46 | 0.350 |
Why?
|
| Coma | 1 | 2011 | 13 | 0.340 |
Why?
|
| Sex Characteristics | 1 | 2012 | 202 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2014 | 677 | 0.340 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2018 | 7 | 0.330 |
Why?
|
| Heart Failure | 1 | 2018 | 926 | 0.330 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 460 | 0.320 |
Why?
|
| Logistic Models | 4 | 2020 | 1270 | 0.320 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2010 | 8 | 0.320 |
Why?
|
| Maze Learning | 2 | 2007 | 55 | 0.320 |
Why?
|
| Functional Laterality | 2 | 2007 | 138 | 0.320 |
Why?
|
| Acute Disease | 3 | 2023 | 671 | 0.310 |
Why?
|
| United States | 8 | 2025 | 7923 | 0.310 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 2482 | 0.310 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 39 | 0.310 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2009 | 2 | 0.310 |
Why?
|
| Head Injuries, Closed | 2 | 2021 | 15 | 0.300 |
Why?
|
| Spatial Behavior | 2 | 2007 | 9 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 3450 | 0.300 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2006 | 17 | 0.300 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 397 | 0.290 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1118 | 0.290 |
Why?
|
| Autophagy | 2 | 2021 | 231 | 0.290 |
Why?
|
| Administration, Oral | 4 | 2025 | 374 | 0.290 |
Why?
|
| Prospective Studies | 5 | 2024 | 3318 | 0.290 |
Why?
|
| Prevalence | 5 | 2026 | 1407 | 0.290 |
Why?
|
| Disease Progression | 3 | 2025 | 1176 | 0.290 |
Why?
|
| Age Factors | 5 | 2024 | 1570 | 0.280 |
Why?
|
| Carcinoma | 1 | 2009 | 129 | 0.280 |
Why?
|
| Patient Admission | 3 | 2020 | 198 | 0.280 |
Why?
|
| Analysis of Variance | 4 | 2015 | 608 | 0.280 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 86 | 0.280 |
Why?
|
| Circle of Willis | 1 | 2007 | 7 | 0.270 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2025 | 49 | 0.270 |
Why?
|
| Nerve Fibers | 1 | 2007 | 30 | 0.270 |
Why?
|
| Incidence | 5 | 2025 | 1385 | 0.270 |
Why?
|
| Electrophysiology | 1 | 2007 | 90 | 0.260 |
Why?
|
| Discrimination Learning | 1 | 2007 | 10 | 0.260 |
Why?
|
| Levodopa | 1 | 2007 | 8 | 0.260 |
Why?
|
| Hyperhomocysteinemia | 1 | 2007 | 6 | 0.260 |
Why?
|
| Nitrous Oxide | 1 | 2007 | 7 | 0.260 |
Why?
|
| Hypotension | 1 | 2007 | 50 | 0.260 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 158 | 0.250 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2007 | 36 | 0.250 |
Why?
|
| Radiography | 3 | 2019 | 553 | 0.250 |
Why?
|
| DNA Repeat Expansion | 2 | 2023 | 58 | 0.250 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 32 | 0.240 |
Why?
|
| Cerebral Angiography | 4 | 2022 | 295 | 0.240 |
Why?
|
| Boronic Acids | 1 | 2006 | 28 | 0.240 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 930 | 0.240 |
Why?
|
| Pyrazines | 1 | 2006 | 35 | 0.240 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2025 | 6 | 0.240 |
Why?
|
| Biomarkers | 4 | 2020 | 1431 | 0.240 |
Why?
|
| Hippocampus | 2 | 2007 | 278 | 0.240 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1164 | 0.240 |
Why?
|
| Brain Edema | 2 | 2021 | 31 | 0.240 |
Why?
|
| Diffusion | 5 | 2010 | 82 | 0.230 |
Why?
|
| Factor Xa Inhibitors | 1 | 2025 | 37 | 0.230 |
Why?
|
| Blood Pressure | 4 | 2010 | 517 | 0.230 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2025 | 3 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2006 | 73 | 0.230 |
Why?
|
| Research | 1 | 2007 | 196 | 0.230 |
Why?
|
| Tetrazolium Salts | 4 | 2009 | 15 | 0.230 |
Why?
|
| Administration, Intravenous | 4 | 2025 | 65 | 0.230 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 412 | 0.220 |
Why?
|
| Posterior Cerebral Artery | 1 | 2024 | 13 | 0.220 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2024 | 26 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 429 | 0.220 |
Why?
|
| Telemedicine | 1 | 2009 | 344 | 0.210 |
Why?
|
| Blood Glucose | 2 | 2020 | 487 | 0.210 |
Why?
|
| Secondary Prevention | 2 | 2021 | 164 | 0.210 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 119 | 0.200 |
Why?
|
| Astrocytes | 2 | 2021 | 121 | 0.200 |
Why?
|
| Epilepsy | 1 | 2024 | 110 | 0.200 |
Why?
|
| Echocardiography | 2 | 2018 | 509 | 0.200 |
Why?
|
| Endarterectomy, Carotid | 1 | 2024 | 79 | 0.200 |
Why?
|
| Mortality | 2 | 2021 | 161 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 248 | 0.200 |
Why?
|
| Skull | 1 | 2023 | 50 | 0.200 |
Why?
|
| Massachusetts | 2 | 2020 | 2096 | 0.200 |
Why?
|
| Blindness | 1 | 2023 | 43 | 0.200 |
Why?
|
| Cerebral Revascularization | 2 | 2024 | 30 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2022 | 23 | 0.190 |
Why?
|
| Simvastatin | 1 | 2022 | 26 | 0.190 |
Why?
|
| Vision Disorders | 1 | 2023 | 67 | 0.190 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 788 | 0.180 |
Why?
|
| Dabigatran | 1 | 2022 | 20 | 0.180 |
Why?
|
| Rats, Inbred WKY | 3 | 2014 | 11 | 0.180 |
Why?
|
| Reflex | 1 | 2021 | 27 | 0.180 |
Why?
|
| Arginine | 1 | 2022 | 131 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1197 | 0.180 |
Why?
|
| RNA Interference | 1 | 2025 | 621 | 0.180 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 215 | 0.180 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 705 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2016 | 587 | 0.170 |
Why?
|
| Mean Platelet Volume | 1 | 2020 | 2 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 859 | 0.160 |
Why?
|
| Hydrocephalus | 1 | 2020 | 43 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2020 | 39 | 0.160 |
Why?
|
| Bed Rest | 1 | 2019 | 11 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 82 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2020 | 105 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 176 | 0.150 |
Why?
|
| CADASIL | 1 | 2019 | 3 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 109 | 0.150 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 147 | 0.150 |
Why?
|
| Neurologic Examination | 1 | 2019 | 53 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 1683 | 0.140 |
Why?
|
| Trauma Severity Indices | 1 | 2018 | 34 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.140 |
Why?
|
| Attention | 1 | 2019 | 148 | 0.140 |
Why?
|
| Random Allocation | 3 | 2007 | 201 | 0.140 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 86 | 0.140 |
Why?
|
| Huntingtin Protein | 1 | 2018 | 145 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2018 | 74 | 0.130 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2019 | 212 | 0.130 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 110 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 186 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 293 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| Adolescent | 3 | 2023 | 6305 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Neurosurgery | 1 | 2017 | 30 | 0.130 |
Why?
|
| Specialization | 1 | 2017 | 80 | 0.130 |
Why?
|
| Neurology | 1 | 2017 | 43 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 128 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 45 | 0.120 |
Why?
|
| Wallerian Degeneration | 1 | 2016 | 8 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 984 | 0.120 |
Why?
|
| Plasminogen Activators | 1 | 2015 | 10 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2016 | 42 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2017 | 218 | 0.120 |
Why?
|
| Catheters | 1 | 2016 | 78 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 92 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 901 | 0.110 |
Why?
|
| Hospitalization | 2 | 2020 | 1368 | 0.110 |
Why?
|
| Glasgow Coma Scale | 1 | 2014 | 48 | 0.110 |
Why?
|
| Software | 2 | 2009 | 388 | 0.110 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 374 | 0.110 |
Why?
|
| Oxygen | 3 | 2022 | 321 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 759 | 0.110 |
Why?
|
| Collateral Circulation | 2 | 2025 | 26 | 0.110 |
Why?
|
| Young Adult | 3 | 2022 | 4781 | 0.110 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 21 | 0.110 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 247 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2017 | 414 | 0.100 |
Why?
|
| Dementia | 1 | 2017 | 263 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 312 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 220 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 267 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1393 | 0.100 |
Why?
|
| Comorbidity | 3 | 2024 | 1119 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 288 | 0.100 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2012 | 6 | 0.100 |
Why?
|
| Research Design | 1 | 2016 | 583 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 498 | 0.100 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2012 | 3 | 0.100 |
Why?
|
| Perfusion Imaging | 2 | 2025 | 22 | 0.100 |
Why?
|
| Nasopharynx | 1 | 2012 | 22 | 0.100 |
Why?
|
| Motor Neurons | 2 | 2025 | 215 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 226 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 192 | 0.090 |
Why?
|
| Dysarthria | 1 | 2011 | 7 | 0.090 |
Why?
|
| Teaching | 1 | 2012 | 164 | 0.090 |
Why?
|
| Carotid Artery, Internal | 2 | 2024 | 68 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 202 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 358 | 0.080 |
Why?
|
| Thalamus | 1 | 2011 | 75 | 0.080 |
Why?
|
| New York City | 2 | 2020 | 91 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2025 | 870 | 0.080 |
Why?
|
| Reaction Time | 2 | 2007 | 126 | 0.080 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2009 | 14 | 0.080 |
Why?
|
| Dogs | 2 | 2022 | 332 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2025 | 406 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2009 | 41 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1257 | 0.070 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Computed Tomography Angiography | 2 | 2022 | 129 | 0.070 |
Why?
|
| Ganglia, Parasympathetic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Cerebral Cortex | 2 | 2006 | 267 | 0.070 |
Why?
|
| Injury Severity Score | 1 | 2007 | 116 | 0.070 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2009 | 180 | 0.070 |
Why?
|
| Space Perception | 1 | 2007 | 19 | 0.070 |
Why?
|
| Catechols | 1 | 2007 | 7 | 0.060 |
Why?
|
| Homocysteine | 1 | 2007 | 33 | 0.060 |
Why?
|
| Silicon | 1 | 2006 | 17 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 375 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2009 | 233 | 0.060 |
Why?
|
| Immunoassay | 1 | 2007 | 71 | 0.060 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 40 | 0.060 |
Why?
|
| Sutures | 1 | 2006 | 41 | 0.060 |
Why?
|
| Coloring Agents | 2 | 2023 | 53 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 126 | 0.060 |
Why?
|
| Nitriles | 1 | 2007 | 79 | 0.060 |
Why?
|
| Perfusion | 1 | 2006 | 72 | 0.060 |
Why?
|
| Sensation Disorders | 1 | 2006 | 21 | 0.060 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2007 | 60 | 0.060 |
Why?
|
| Movement Disorders | 1 | 2006 | 25 | 0.060 |
Why?
|
| Autoradiography | 1 | 2006 | 53 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 726 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 467 | 0.060 |
Why?
|
| Bortezomib | 1 | 2006 | 56 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 320 | 0.060 |
Why?
|
| Surface Properties | 1 | 2006 | 281 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 134 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 2370 | 0.060 |
Why?
|
| Europe | 1 | 2025 | 197 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 114 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 294 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 373 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 40 | 0.050 |
Why?
|
| Heart Rate | 1 | 2005 | 328 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 299 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2025 | 226 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2024 | 61 | 0.050 |
Why?
|
| Intravital Microscopy | 1 | 2023 | 12 | 0.050 |
Why?
|
| Arteries | 1 | 2024 | 80 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 48 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 783 | 0.050 |
Why?
|
| Headache | 1 | 2023 | 58 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 20 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 11 | 0.050 |
Why?
|
| Head | 1 | 2023 | 54 | 0.050 |
Why?
|
| Dipeptides | 1 | 2022 | 68 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 577 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 192 | 0.050 |
Why?
|
| Inpatients | 1 | 2024 | 303 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2024 | 856 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 318 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 507 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2025 | 432 | 0.040 |
Why?
|
| Alberta | 1 | 2020 | 4 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2022 | 196 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 129 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 7 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 120 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 31 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 13 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 36 | 0.040 |
Why?
|
| Mutation | 1 | 2009 | 2633 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 59 | 0.040 |
Why?
|
| Migraine with Aura | 1 | 2020 | 2 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2021 | 134 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 207 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 423 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 429 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 471 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 364 | 0.040 |
Why?
|
| Mannitol | 1 | 2018 | 14 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 735 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 206 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 32 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2018 | 61 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2018 | 44 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 861 | 0.030 |
Why?
|
| Light | 1 | 2018 | 204 | 0.030 |
Why?
|
| International Agencies | 1 | 2017 | 7 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 272 | 0.030 |
Why?
|
| Hypercapnia | 2 | 2006 | 9 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2016 | 79 | 0.030 |
Why?
|
| Suction | 1 | 2016 | 35 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 379 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 107 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2007 | 234 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2017 | 155 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 221 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 362 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 381 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 350 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 388 | 0.030 |
Why?
|
| Curriculum | 1 | 2017 | 607 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 70 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2011 | 5 | 0.020 |
Why?
|
| Annexin A2 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2018 | 802 | 0.020 |
Why?
|
| Fibrin | 1 | 2011 | 19 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2011 | 33 | 0.020 |
Why?
|
| Xenon Isotopes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Protons | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2621 | 0.020 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2009 | 15 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 43 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2738 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 2006 | 8 | 0.020 |
Why?
|
| Kidney | 1 | 2009 | 455 | 0.020 |
Why?
|
| Sensation | 1 | 2006 | 19 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 86 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 391 | 0.010 |
Why?
|
| Nerve Net | 1 | 2006 | 99 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 136 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 1223 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 334 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2004 | 2 | 0.010 |
Why?
|
| Ischemia | 1 | 2005 | 196 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 304 | 0.010 |
Why?
|